EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In Vitro and In Vivo Pharmacological Profiles of LENART01, a Dermorphin–Ranatensin Hybrid Peptide

Nadine Hochrainer, Pawel Serafin, Sara D'Ingiullo, Adriano Mollica iD, Sebastian Granica iD, Marek Brytan iD, Patrycja Kleczkowska iD, Mariana Spetea iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25074007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Nadine Hochrainer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Institute of Pharmacy and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, 6020 In…. Hauptthemen laut MEDLINE: Analgesics, Opioid, Receptors, Opioid, Oligopeptides. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Austrian Science Fund, University of Innsbruck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diverse chemical and pharmacological strategies are currently being explored to minimize the unwanted side effects of currently used opioid analgesics while achieving effective pain relief. The use of multitarget ligands with activity at more than one receptor represents a promising therapeutic approach. We recently reported a bifunctional peptide-based hybrid LENART01 combining dermorphin and ranatensin pharmacophores, which displays activity to the mu-opioid receptor (MOR) and dopamine D2 receptor (D2R) in rat brains and spinal cords. In this study, we investigated the in vitro binding and functional activities to the human MOR and the in vivo pharmacology of LENART01 in mice after subcutaneous administration. In vitro binding assays showed LENART01 to bind and be selective to the human MOR over the other opioid receptor subtypes and delta, kappa and nociceptin receptors. In the [35S]GTPγS binding assay, LENART01 acted as a potent and full agonist to the human MOR. In mice, LENART01 produced dose-dependent antinociceptive effects in formalin-induced inflammatory pain, with increased potency than morphine. Antinociceptive effects were reversed by naloxone, indicating MOR activation in vivo. Behavioral studies also demonstrated LENART01’s properties to induce less adverse effects without locomotor dysfunction and withdrawal syndrome compared to conventional opioid analgesics, such as morphine. LENART01 is the first peptide-based MOR-D2R ligand known to date and the first dual MOR-dopamine D2R ligand for which in vivo pharmacology is reported with antinociceptive efficacy and reduced opioid-related side effects. Our current findings may pave the way to new pain therapeutics with limited side effects in acute and chronic use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Analgesics, OpioidReceptors, OpioidOligopeptidesHumansRatsAnimalsMiceLigandsMorphineOpioid PeptidesPainPyrrolidonecarboxylic Acid

Stichwörter der Autor:innen

antinociceptiondermorphindopamine receptorsformalin testinflammatory painmultitarget ligandsopioid receptorsranatensinside effectstail-flick test

Substanzen

ranatensindermorphinAnalgesics, OpioidLigandsReceptors, OpioidMorphineOpioid PeptidesOligopeptidesPyrrolidonecarboxylic Acid

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Institute of Pharmacy and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, 6020 Innsbruck, Austria.
  • Military Institute of Hygiene and Epidemiology, 01-163 Warsaw, Poland.
  • Department of Pharmacy, University "G. d'Annunzio" of Chieti-Pescara, Via dei Vestini 31, 66100 Chieti, Italy.
  • Microbiota Lab, Department of Pharmacognosy and Molecular Basis of Phytotherapy, Medical University of Warsaw, 02-097 Warsaw, Poland.
  • Maria Sklodowska-Curie Medical Academy in Warsaw, 03-411 Warsaw, Poland.

ORCID-Profile: Adriano Mollica, Sebastian Granica, Marek Brytan, Patrycja Kleczkowska, Mariana Spetea

Förderung

  • Austrian Science Fund
  • University of Innsbruck

Zitieren

APA

Hochrainer, N., Serafin, P., D'Ingiullo, S., Mollica, A., Granica, S., Brytan, M., Kleczkowska, P., & Spetea, M. (2024). In Vitro and In Vivo Pharmacological Profiles of LENART01, a Dermorphin–Ranatensin Hybrid Peptide. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25074007

Vancouver

Hochrainer N, Serafin P, D'Ingiullo S, Mollica A, Granica S, Brytan M, et al. In Vitro and In Vivo Pharmacological Profiles of LENART01, a Dermorphin–Ranatensin Hybrid Peptide. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25074007

BibTeX
@article{Hochrainer2024,
  author = {Hochrainer, Nadine and Serafin, Pawel and D'Ingiullo, Sara and Mollica, Adriano and Granica, Sebastian and Brytan, Marek and Kleczkowska, Patrycja and Spetea, Mariana},
  title = {In Vitro and In Vivo Pharmacological Profiles of LENART01, a Dermorphin–Ranatensin Hybrid Peptide},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25074007}
}
Kostenlos starten →